Trial Profile
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Sep 2021
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Actavis
- 06 Jan 2020 Status changed from recruiting to completed.
- 05 Dec 2018 New trial record